Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Mallinckrodt
McKesson
AstraZeneca
Dow

Last Updated: June 27, 2022

IMIPRAMINE PAMOATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Imipramine Pamoate patents expire, and what generic alternatives are available?

Imipramine Pamoate is a drug marketed by Hikma, Lupin Ltd, and Rising. and is included in three NDAs.

The generic ingredient in IMIPRAMINE PAMOATE is imipramine pamoate. There are thirty-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the imipramine pamoate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Imipramine Pamoate

A generic version of IMIPRAMINE PAMOATE was approved as imipramine pamoate by HIKMA on April 16th, 2010.

  Try it Free

Drug patent expirations by year for IMIPRAMINE PAMOATE
Drug Prices for IMIPRAMINE PAMOATE

See drug prices for IMIPRAMINE PAMOATE

Recent Clinical Trials for IMIPRAMINE PAMOATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Shalvata Mental Health CenterN/A
Roxane LaboratoriesN/A

See all IMIPRAMINE PAMOATE clinical trials

Pharmacology for IMIPRAMINE PAMOATE
Anatomical Therapeutic Chemical (ATC) Classes for IMIPRAMINE PAMOATE

US Patents and Regulatory Information for IMIPRAMINE PAMOATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma IMIPRAMINE PAMOATE imipramine pamoate CAPSULE;ORAL 091099-001 Apr 16, 2010 AB RX No Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lupin Ltd IMIPRAMINE PAMOATE imipramine pamoate CAPSULE;ORAL 090444-003 Apr 16, 2010 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Hikma IMIPRAMINE PAMOATE imipramine pamoate CAPSULE;ORAL 091099-004 Apr 16, 2010 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Moodys
Harvard Business School
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.